AbbVie Venclexta, Abbott CDx Approval Provide Docs Opportunity to Individualize CLL Treatment | GenomeWeb

NEW YORK (GenomeWeb) – The US Food and Drug Administration this week approved a new personalized, oral drug for a molecularly defined subset of chronic lymphocytic leukemia (CLL) patients who have relapsed or are refractory to chemotherapy.

Venclexta (venetoclax), which AbbVie developed and markets with Genentech in the US, targets B-cell lymphoma 2, a commonly overexpressed protein known to drive cancer in CLL patients. The agency approved the drug for patients who have received prior therapy and have a 17p deletion as detected by Abbott Molecular's Vysis CLL FISH probe kit.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.